0001420800-26-000020 | 10-Q | XBRL Viewer

Print Document

Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Apr. 03, 2026	Dec. 31, 2025
Accrued Liabilities [Abstract]
Accrued compensation and related benefits	$ 77,090	$ 105,112
Accrued taxes	60,335	27,178
Derivative liability – current portion	48,257	51,485
Accrued third-party commissions	34,691	38,174
Lease liability – current portion	25,227	24,742
Accrued rebates	21,783	31,033
Accrued professional fees	14,873	11,495
Accrued interest	9,641	4,193
Deferred and contingent consideration – current portion	6,644	8,873
Customer advances and billings in excess of costs incurred	6,082	6,495
Accrued restructuring liability	5,814	7,975
Accrued freight	5,267	4,876
Accrued royalties	4,976	4,990
Purchase of royalty interest – current portion	4,247	6,430
Warranty liability	2,633	2,621
Other	32,483	40,271
Accrued liabilities	$ 360,043	$ 375,943

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Apr. 03, 2026	Apr. 04, 2025	Dec. 31, 2025
Cash flows from operating activities:
Net income (loss)	$ (8,450)	$ (55,705)
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	73,355	71,435
Stock-based compensation expense	8,750	7,407
Non-cash interest expense	1,788	1,348
Fair value loss on contingent acquisition shares	0	1,787
Deferred income tax benefit	(37,711)	(1,769)
Loss (gain) on sale of property, plant and equipment	(75)	(527)
Changes in operating assets and liabilities:
Trade receivables, net	(4,347)	(15,977)
Inventories, net	(22,072)	(23,295)
Accounts payable	26,887	4,189
Other operating assets and liabilities	(14,174)	9,511
Net cash provided by (used in) operating activities	23,951	(1,596)
Cash flows from investing activities:
Purchases of property, plant and equipment and intangibles	(52,804)	(43,262)
Payments for acquisitions, net of cash received, and investments	(291)	(18,858)
Cash received upon settlement of derivatives	0	1,601
Net cash used in investing activities	(53,095)	(60,519)
Cash flows from financing activities:
Repayments of borrowings under term credit facility	(8,750)	(5,000)
Proceeds from borrowings on revolving credit facilities and other	72,000	72,000
Repayments of borrowings on revolving credit facilities and other	(35,516)	(10,438)
Payments of tax withholding for stock-based awards	(943)	(3,447)
Proceeds from issuance of common stock, net	628	341
Deferred consideration payments and other	(1,396)	(2,265)
Net cash provided by financing activities	26,023	51,191
Effect of foreign exchange rates on Cash and cash equivalents	(139)	1,217
Decrease in Cash and cash equivalents	(3,260)	(9,707)
Cash and cash equivalents, beginning of period	36,389	48,167	$ 48,167
Cash and cash equivalents, end of period	$ 33,129	$ 38,460	$ 36,389

CONDENSED CONSOLIDATED STATEMENT OF EQUITY Statement of Stockholders' Equity [Parenthetical] - USD ($) $ in Thousands	3 Months Ended
	Apr. 03, 2026	Apr. 04, 2025
Statement of Stockholders' Equity [Abstract]
Other comprehensive income (loss), tax (benefit)	$ 37	$ (13,185)

- Definition

Amount of tax expense (benefit) allocated to other comprehensive income (loss).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 12
-SubTopic 10
-Topic 220
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-12

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-4

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481674/830-30-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-17

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-20

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-10

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482659/740-20-45-11

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482659/740-20-45-2

+ Details

Accrued Liabilities - Restructuring Rollforward (Details) $ in Thousands	3 Months Ended
	Apr. 03, 2026 USD ($)
Restructuring Reserve [Roll Forward]
Balance at Beginning of Period	$ 7,975
Provisions	2,708
Payments	(4,870)
Foreign Currency Translation	1
Balance at End of Period	5,814
Prevention & Recovery
Restructuring Reserve [Roll Forward]
Provisions	1,400
Reconstructive
Restructuring Reserve [Roll Forward]
Provisions	1,300
Termination benefits
Restructuring Reserve [Roll Forward]
Balance at Beginning of Period	7,975
Provisions	1,290
Payments	(3,452)
Foreign Currency Translation	1
Balance at End of Period	5,814
Facility closure costs
Restructuring Reserve [Roll Forward]
Balance at Beginning of Period	0
Provisions	1,418
Payments	(1,418)
Foreign Currency Translation	0
Balance at End of Period	$ 0

Net Income (Loss) Per Share from Continuing Operations

3 Months Ended

Apr. 03, 2026

Earnings Per Share [Abstract]

Net Income (Loss) Per Share from Continuing Operations

Net income (loss) per share from continuing operations was computed using the treasury stock method as follows:


	Three Months Ended
	April 3, 2026		April 4, 2025
	(In thousands, except share and per share data)
Computation of Net income (loss) per share from continuing operations - basic:
Net income (loss) from continuing operations attributable to Enovis Corporation(1)	$	(8,725)	$	(55,841)
Weighted-average shares of Common stock outstanding – basic	57,313,036		56,791,836
Net income (loss) per share from continuing operations – basic	$	(0.15)	$	(0.98)

Computation of Net income (loss) per share from continuing operations - diluted:
Net income (loss) from continuing operations attributable to Enovis Corporation(1)	$	(8,725)	$	(55,841)
Weighted-average shares of Common stock outstanding – basic	57,313,036		56,791,836
Net effect of potentially dilutive securities - stock options and restricted stock units	—		—
Weighted-average shares of Common stock outstanding – diluted	57,313,036		56,791,836
Net income (loss) per share from continuing operations – diluted	$	(0.15)	$	(0.98)

(1) Net income (loss) from continuing operations attributable to Enovis Corporation for the respective periods is calculated using Net income (loss) from continuing operations less the continuing operations component of the income attributable to noncontrolling interest, net of taxes.

The following table presents the potentially dilutive shares of Common stock from stock-based compensation awards excluded from the calculation of Weighted-average shares of Common stock outstanding – diluted as inclusion would be anti-dilutive in Net income (loss) per share (“Anti-dilutive shares”):

Three Months Ended

April 3, 2026

April 4, 2025

Anti-dilutive shares

2,301,362

1,867,454

Recently Issued Accounting Pronouncements (Policies)	3 Months Ended
Recently Issued Accounting Pronouncements (Policies)	Apr. 03, 2026
Accounting Policies [Abstract]
Basis of Accounting	The Condensed Consolidated Financial Statements included in this quarterly report have been prepared by the Company in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) and accounting principles generally accepted in the United States of America (“GAAP”) for interim financial statements and reflect, in the opinion of management, all adjustments, which consist solely of normal recurring adjustments, necessary to present fairly the Company’s financial position and results of operations as of and for the periods indicated. The Condensed Consolidated Balance Sheet as of December 31, 2025 is derived from the Company’s audited financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been omitted in accordance with the SEC’s rules and regulations for interim financial statements.
Use of Estimates	The Company makes certain estimates and assumptions in preparing its Condensed Consolidated Financial Statements in accordance with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the Condensed Consolidated Financial Statements, and the reported amounts of revenues and expenses for the periods presented. Actual results may differ from those estimates.
New Accounting Pronouncements	The Company is currently reviewing updated disclosure requirements related to (“ASU”) 2024-03, Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The amendments in this ASU clarify the requirements for certain categories of expenses included in expense line items on the face of the income statement to be disclosed in a disaggregated manner in the notes to the financial statements. In addition, the update requires that the entity disclose both the total amount of selling expenses reported and how it defines selling expenses. Update No. 2024-03 is effective, as clarified by ASU No. 2025-01, for public business entities for annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. The Company is currently reviewing updated disclosure requirements related to (“ASU”) 2025-09 — Derivatives and Hedging (Topic 815): Hedge Accounting Improvements. This updates certain aspects of hedge accounting guidance to better reflect an entity’s risk management activities in its financial statements. Update No. 2025-09 is effective for all annual reporting periods beginning after December 15, 2026, and interim periods within those annual reporting periods. The Company is currently evaluating the impact of this ASU on its consolidated financial statement disclosures. Other recently issued accounting pronouncements are not expected to have a material impact on the Company's consolidated financial statements.

Inventories, Net (Tables)

3 Months Ended

Apr. 03, 2026

Inventory Disclosure [Abstract]

Schedule of Inventory

Inventories, net consisted of the following:


	April 3, 2026		December 31, 2025
	(In thousands)
Raw materials	$	119,224	$	120,634
Work in process	59,472		54,895
Finished goods	511,998		497,568
	690,694		673,097
Less: Allowance for excess, slow-moving and obsolete inventory	(88,151)		(88,718)
	$	602,543	$	584,379

Equity - AOCL Components (Details) - USD ($) $ in Thousands	3 Months Ended
Equity - AOCL Components (Details) - USD ($) $ in Thousands	Apr. 03, 2026	Apr. 04, 2025
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, beginning	$ 1,491,902	$ 2,564,329
Foreign currency translation adjustment	(17,381)	104,806
Gain (loss) on hedge activity	6,243	(41,493)
Other comprehensive income (loss) before reclassifications	(11,138)	63,321
Amounts reclassified from Accumulated other comprehensive loss	(1,258)	(419)
Net current period other comprehensive income (loss)	(12,396)	62,902
Balance, ending	1,479,492	2,620,218
Accumulated Other Comprehensive Loss
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, beginning	(91,363)	(127,892)
Balance, ending	(103,759)	(64,990)
Net Unrecognized Pension Benefit Cost
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, beginning	9,856	8,412
Foreign currency translation adjustment	(89)	(3)
Gain (loss) on hedge activity	0	0
Other comprehensive income (loss) before reclassifications	(89)	5
Amounts reclassified from Accumulated other comprehensive loss	(190)	(34)
Net current period other comprehensive income (loss)	(279)	(29)
Balance, ending	9,577	8,383
Foreign Currency Translation Adjustment
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, beginning	81,624	(113,664)
Foreign currency translation adjustment	(17,292)	104,809
Gain (loss) on hedge activity	0	0
Other comprehensive income (loss) before reclassifications	(17,292)	104,809
Amounts reclassified from Accumulated other comprehensive loss	0	0
Net current period other comprehensive income (loss)	(17,292)	104,809
Balance, ending	64,332	(8,855)
Unrealized Gain (Loss) on Hedging Activities
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, beginning	(182,843)	(22,640)
Foreign currency translation adjustment	0	0
Gain (loss) on hedge activity	6,243	(41,493)
Other comprehensive income (loss) before reclassifications	6,243	(41,493)
Amounts reclassified from Accumulated other comprehensive loss	(1,068)	(385)
Net current period other comprehensive income (loss)	5,175	(41,878)
Balance, ending	$ (177,668)	(64,518)
Accumulated Defined Benefit Plans Adjustment Attributable to Parent
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Net actuarial gain		$ 8

General (Details)	3 Months Ended
General (Details)	Apr. 03, 2026 segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of operating segments	2
Number of reportable segments	2

Net Income (Loss) Per Share from Continuing Operations - Schedule of Antidilutive Securities (Details) - shares	3 Months Ended
	Apr. 03, 2026	Apr. 04, 2025
Earnings Per Share [Abstract]
Anti-dilutive shares (in shares)	2,301,362	1,867,454

Revenue - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 03, 2026	Apr. 04, 2025
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	$ 589,151	$ 558,834
Prevention & Recovery
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	272,018	272,584
Prevention & Recovery \| Bracing and Support \| U.S.
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	114,883	115,086
Prevention & Recovery \| Other Prevention and Recovery \| U.S.
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	55,862	66,622
Prevention & Recovery \| Prevention & Recovery \| International
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	101,273	90,876
Reconstructive
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	317,133	286,250
Reconstructive \| Surgical \| U.S.
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	149,208	137,877
Reconstructive \| Surgical \| International
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	$ 167,925	$ 148,373

Acquisitions, Investments and Divestitures (Details)		3 Months Ended		12 Months Ended
Acquisitions, Investments and Divestitures (Details)	Oct. 07, 2025 USD ($)	Apr. 03, 2026 USD ($) investment	Apr. 04, 2025 USD ($)	Dec. 31, 2025 USD ($) businessCombination acquisition
Business Acquisition [Line Items]
Number of business combinations completed \| businessCombination				5
Number of asset acquisitions completed \| acquisition				2
Acquisition, net of cash received		$ 291,000	$ 18,858,000
Goodwill		$ 711,903,000		$ 718,299,000
Equity securities without readily determinable fair value, number of investments \| investment		1
Equity investment without readily determinable fair value		$ 22,400,000
Equity investment without readily determinable fair value, impairment		0
Equity investment without readily determinable fair value, upward adjustment		$ 0
Held-for-Sale \| Dr Comfort Footcare Solutions
Business Acquisition [Line Items]
Divestiture consideration	$ 60,000,000.0
Upfront payment	45,000,000.0
Future payable upon achievement of certain milestones	$ 15,000,000.0
Asset Acquisitions 2025
Business Acquisition [Line Items]
Definite-lived intangible assets acquired				16,300,000
Asset Acquisitions 2025 \| Prevention & Recovery
Business Acquisition [Line Items]
Payments for asset acquisitions				6,500,000
Asset acquisition, contingent consideration liability				8,300,000
Asset Acquisitions 2025 \| Reconstructive
Business Acquisition [Line Items]
Payments for asset acquisitions				1,500,000
2025 Acquisitions
Business Acquisition [Line Items]
Acquisition consideration				36,900,000
Intangible assets acquired				$ 20,700,000
2025 Acquisitions \| Prevention & Recovery
Business Acquisition [Line Items]
Number of acquisitions \| acquisition				2
Acquisition, net of cash received				$ 7,800,000
Contingent consideration, liability				$ 1,900,000
2025 Acquisitions \| Reconstructive
Business Acquisition [Line Items]
Number of acquisitions \| acquisition				3
Acquisition, net of cash received				$ 9,700,000
Contingent consideration, liability				$ 1,000,000.0

General	3 Months Ended
General	Apr. 03, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]
General	General Enovis Corporation (the “Company” or “Enovis”) is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. The Company conducts its business through two operating segments, Prevention & Recovery (“P&R”) and Reconstructive (“Recon”). The P&R segment provides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative disease. The Recon segment provides surgical implant solutions, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools. The Condensed Consolidated Financial Statements included in this quarterly report have been prepared by the Company in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) and accounting principles generally accepted in the United States of America (“GAAP”) for interim financial statements and reflect, in the opinion of management, all adjustments, which consist solely of normal recurring adjustments, necessary to present fairly the Company’s financial position and results of operations as of and for the periods indicated. The Condensed Consolidated Balance Sheet as of December 31, 2025 is derived from the Company’s audited financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been omitted in accordance with the SEC’s rules and regulations for interim financial statements. The Condensed Consolidated Financial Statements included herein should be read in conjunction with the audited financial statements and related footnotes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 (the “2025 Form 10-K”), filed with the SEC on February 26, 2026. The Company makes certain estimates and assumptions in preparing its Condensed Consolidated Financial Statements in accordance with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the Condensed Consolidated Financial Statements, and the reported amounts of revenues and expenses for the periods presented. Actual results may differ from those estimates.

Accrued Liabilities (Tables)

3 Months Ended

Apr. 03, 2026

Accrued Liabilities [Abstract]

Schedule of Accrued Liabilities

Accrued liabilities in the Condensed Consolidated Balance Sheets consisted of the following:


	April 3, 2026		December 31, 2025
	(In thousands)
Accrued compensation and related benefits	$	77,090	$	105,112
Accrued taxes	60,335		27,178
Derivative liability – current portion	48,257		51,485
Accrued third-party commissions	34,691		38,174
Lease liability – current portion	25,227		24,742
Accrued rebates	21,783		31,033
Accrued professional fees	14,873		11,495
Accrued interest	9,641		4,193
Deferred and contingent consideration – current portion	6,644		8,873
Customer advances and billings in excess of costs incurred	6,082		6,495
Accrued restructuring liability	5,814		7,975
Accrued freight	5,267		4,876
Accrued royalties	4,976		4,990
Purchase of royalty interest – current portion	4,247		6,430
Warranty liability	2,633		2,621
Other	32,483		40,271
	$	360,043	$	375,943

Summary of Restructuring Liability

A summary of the activity in the Company’s restructuring liability included in Accrued liabilities in the Condensed Consolidated Balance Sheets is as follows:


	Three Months Ended April 3, 2026
	Balance at Beginning of Period		Provisions		Payments		Foreign Currency Translation		Balance at End of Period
	(In thousands)
Restructuring charges:
Termination benefits(1)	$	7,975	$	1,290	$	(3,452)	$	1	$	5,814
Facility closure costs and other(2)	—		1,418		(1,418)		—		—
Total (3)	$	7,975	$	2,708	$	(4,870)	$	1	$	5,814

(1) Includes severance and other termination benefits, including outplacement services.

(2) Includes the cost of relocating associates, relocating equipment, lease termination expense and other costs in connection with the closure and optimization of office sites, shared service centers, and manufacturing facilities.

(3) For the three months ended April 3, 2026, $1.4 million and $1.3 million of the Company’s total provisions were related to the P&R and Recon segments, respectively.

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Apr. 03, 2026	Apr. 04, 2025
Income Tax Disclosure [Abstract]
Loss from continuing operations before income taxes	$ 634	$ (57,349)
Income tax expense (benefit)	$ 9,045	$ (1,769)

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-10

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Subparagraph (a)
-SubTopic 20
-Topic 740
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482659/740-20-45-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-SubTopic 10
-Topic 235
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

+ Details

Debt - Textual (Details) $ / shares in Units, $ in Millions				3 Months Ended
Debt - Textual (Details) $ / shares in Units, $ in Millions	Dec. 08, 2025 USD ($)	Jan. 03, 2024 USD ($)	Oct. 24, 2023 USD ($) day $ / shares	Apr. 03, 2026 USD ($)	Oct. 23, 2023 USD ($)	Apr. 04, 2022
Debt Instrument [Line Items]
Letters of credit and surety bonds outstanding				$ 49.6
Deferred financing costs				5.3
Original issue discount fees and issuance costs				10.7
Interest Rate Cap
Debt Instrument [Line Items]
Derivative, Market Price, Initial Cap Price \| $ / shares			$ 89.72
Overdraft Facilities \| Line of Credit
Debt Instrument [Line Items]
Credit facility				$ 30.0
Enovis Credit Agreement \| Revolving Credit Facility \| Line of Credit
Debt Instrument [Line Items]
Credit facility					$ 1,100.0
Debt covenant, maximum total leverage ratio						3.50
Debt instrument covenant minimum interest coverage ratio						3.00
Repayment of outstanding principal balance	$ 335.0
Weighted average interest rate				5.19%
Amount available on the Revolver				$ 906.0
Enovis Credit Agreement \| Secured Debt \| Line of Credit
Debt Instrument [Line Items]
Principal amount					700.0
Quarterly principal repayment percentage		1.25%
Required quarterly principal repayments		$ 8.8
Enovis Credit Agreement \| Bridge Loan \| Line of Credit
Debt Instrument [Line Items]
Credit facility					$ 50.0
2028 Convertible Senior Notes \| Senior unsecured convertible notes
Debt Instrument [Line Items]
Principal amount			$ 460.0
Debt instrument, interest rate, stated percentage			3.875%
Debt convertible, conversion price (in usd per share) \| $ / shares			$ 58.32
Effective interest rate			4.60%
Interest expense				5.3
Interest expense based upon coupon rate				4.5
Accretion of debt discount				$ 0.7
Debt convertible, conversion ratio			0.0171474
2028 Convertible Senior Notes \| Senior unsecured convertible notes \| Debt Conversion Terms One
Debt Instrument [Line Items]
Business day threshold \| day			20
Consecutive trading days threshold \| day			30
Debt convertible, threshold percentage of stock price trigger (in usd per share)			130.00%
2028 Convertible Senior Notes \| Senior unsecured convertible notes \| Debt Conversion Terms Two
Debt Instrument [Line Items]
Business day threshold \| day			5
Consecutive trading days threshold \| day			5
Debt convertible, threshold percentage of stock price trigger (in usd per share)			98.00%
Amended Credit Agreement \| Senior unsecured convertible notes
Debt Instrument [Line Items]
Debt convertible, conversion ratio			17.1474

Equity (Tables)

3 Months Ended

Apr. 03, 2026

Equity [Abstract]

Schedule of Accumulated Other Comprehensive Loss

The following tables present the changes in the balances of each component of Accumulated other comprehensive income (loss) including reclassifications out of Accumulated other comprehensive loss for the three months ended April 3, 2026 and April 4, 2025. All amounts are presented net of tax and noncontrolling interest, if any.


	Accumulated Other Comprehensive Loss Components
	Net Unrecognized Pension Benefit Cost		Foreign Currency Translation Adjustment		Unrealized Gain (Loss) on Hedging Activities		Total
	(In thousands)

Balance at January 1, 2026	$	9,856	$	81,624	$	(182,843)	$	(91,363)

Other comprehensive income (loss) before reclassifications:


Foreign currency translation adjustment	(89)		(17,292)		—		(17,381)

Gain on hedge activity	—		—		6,243		6,243


Other comprehensive income (loss) before reclassifications	(89)		(17,292)		6,243		(11,138)
Amounts reclassified from Accumulated other comprehensive income (loss)	(190)		—		(1,068)		(1,258)

Net Other comprehensive income (loss)	(279)		(17,292)		5,175		(12,396)

Balance at April 3, 2026	$	9,577	$	64,332	$	(177,668)	$	(103,759)


	Accumulated Other Comprehensive Loss Components
	Net Unrecognized Pension Benefit Cost		Foreign Currency Translation Adjustment		Unrealized Loss on Hedging Activities		Total
	(In thousands)
Balance at January 1, 2025	$	8,412	$	(113,664)	$	(22,640)	$	(127,892)

Other comprehensive income (loss) before reclassifications:
Net actuarial gain	8		—		—		8
Foreign currency translation adjustment	(3)		104,809		—		104,806

Loss on hedge activity	—		—		(41,493)		(41,493)


Other comprehensive income (loss) before reclassifications	5		104,809		(41,493)		63,321
Amounts reclassified from Accumulated other comprehensive income (loss)	(34)		—		(385)		(419)

Net Other comprehensive income (loss)	(29)		104,809		(41,878)		62,902

Balance at April 4, 2025	$	8,383	$	(8,855)	$	(64,518)	$	(64,990)

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Apr. 03, 2026
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Net Income (Loss) Per Share from Continuing Operations - Schedule of Earnings per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Apr. 03, 2026	Apr. 04, 2025
Earnings Per Share [Abstract]
Net loss from continuing operations attributable to Parent	$ (8,725)	$ (55,841)
Weighted-average shares of Common stock outstanding - basic (in shares)	57,313,036	56,791,836
Net loss per share from continuing operations-basic (in usd per share)	$ (0.15)	$ (0.98)
Net effect of potentially dilutive securities - stock options and restricted stock units (in shares)	0	0
Weighted-average shares of Common stock outstanding - diluted (in shares)	57,313,036	56,791,836
Net loss per share from continuing operations - diluted (in usd per share)	$ (0.15)	$ (0.98)

- Definition

The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.

+ References

+ Details

- Definition

The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

+ Details

Financial Instruments and Fair Value Measurements-Contingent Consideration Liability (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 03, 2026	Apr. 04, 2025
Business Combination, Contingent Consideration, Liability [Roll Forward]
Charges / (Gain)	$ 0	$ 1,787
Fair Value, Inputs, Level 3
Business Combination, Contingent Consideration, Liability [Roll Forward]
Contingent Consideration, Beginning Balance	15,699
Additions	0
Charges / (Gain)	0
Interest	0
Payments	0
Foreign Exchange	352
Contingent Consideration, Ending Balance	$ 16,051

Inventories, Net

3 Months Ended

Apr. 03, 2026

Inventory Disclosure [Abstract]

Inventories, Net

Inventories, net consisted of the following:


	April 3, 2026		December 31, 2025
	(In thousands)
Raw materials	$	119,224	$	120,634
Work in process	59,472		54,895
Finished goods	511,998		497,568
	690,694		673,097
Less: Allowance for excess, slow-moving and obsolete inventory	(88,151)		(88,718)
	$	602,543	$	584,379

Inventories, Net (Details) - USD ($) $ in Thousands	Apr. 03, 2026	Dec. 31, 2025
Inventory Disclosure [Abstract]
Raw materials	$ 119,224	$ 120,634
Work in process	59,472	54,895
Finished goods	511,998	497,568
Inventory, gross	690,694	673,097
Less: Allowance for excess, slow-moving and obsolete inventory	(88,151)	(88,718)
Inventories, net	$ 602,543	$ 584,379

Financial Instruments and Fair Value Measurements Derivative Instruments in Consolidated Balance Sheet (Details) - USD ($) $ in Thousands	Apr. 03, 2026	Dec. 31, 2025
Designated As Hedging Instrument
Derivative [Line Items]
Derivative asset	$ 29,975	$ 34,176
Derivative liability	165,902	222,151
Not Designated As Hedging Instrument
Derivative [Line Items]
Derivative asset	41,087	34,176
Derivative liability	214,683	222,151
Forward Currency Contracts \| Designated As Hedging Instrument
Derivative [Line Items]
Derivative asset	$ 7,802	$ 0
Derivative Asset, Statement of Financial Position [Extensible Enumeration]	Other current assets	Other current assets
Currency Swap \| Designated As Hedging Instrument
Derivative [Line Items]
Derivative asset	$ 22,173	$ 34,176
Currency Swap \| Designated As Hedging Instrument \| Accrued Expenses
Derivative [Line Items]
Derivative liability	48,257	51,485
Currency Swap \| Designated As Hedging Instrument \| Other Noncurrent Liabilities
Derivative [Line Items]
Derivative liability	117,645	170,666
Currency Swap \| Not Designated As Hedging Instrument
Derivative [Line Items]
Derivative asset	11,112	0
Derivative liability	$ 48,781	$ 0

Equity

3 Months Ended

Apr. 03, 2026

Equity [Abstract]

Equity

7. Equity

Share Repurchase Program

In 2018, the Company’s Board of Directors authorized the repurchase of shares of the Company’s Common stock from time-to-time on the open market or in privately negotiated transactions. No repurchases of the Company’s Common stock have been made under this plan since the third quarter of 2018. As of April 3, 2026, the remaining stock repurchase authorization provided by the Board of Directors was $100 million. The timing, amount and method of shares repurchased is determined by management based on its evaluation of market conditions and other factors. There is no term associated with the remaining repurchase authorization.

Accumulated Other Comprehensive Income (Loss)


	Accumulated Other Comprehensive Loss Components
	Net Unrecognized Pension Benefit Cost		Foreign Currency Translation Adjustment		Unrealized Gain (Loss) on Hedging Activities		Total
	(In thousands)

Balance at January 1, 2026	$	9,856	$	81,624	$	(182,843)	$	(91,363)

Other comprehensive income (loss) before reclassifications:


Foreign currency translation adjustment	(89)		(17,292)		—		(17,381)

Gain on hedge activity	—		—		6,243		6,243


Other comprehensive income (loss) before reclassifications	(89)		(17,292)		6,243		(11,138)
Amounts reclassified from Accumulated other comprehensive income (loss)	(190)		—		(1,068)		(1,258)

Net Other comprehensive income (loss)	(279)		(17,292)		5,175		(12,396)

Balance at April 3, 2026	$	9,577	$	64,332	$	(177,668)	$	(103,759)


	Accumulated Other Comprehensive Loss Components
	Net Unrecognized Pension Benefit Cost		Foreign Currency Translation Adjustment		Unrealized Loss on Hedging Activities		Total
	(In thousands)
Balance at January 1, 2025	$	8,412	$	(113,664)	$	(22,640)	$	(127,892)

Other comprehensive income (loss) before reclassifications:
Net actuarial gain	8		—		—		8
Foreign currency translation adjustment	(3)		104,809		—		104,806

Loss on hedge activity	—		—		(41,493)		(41,493)


Other comprehensive income (loss) before reclassifications	5		104,809		(41,493)		63,321
Amounts reclassified from Accumulated other comprehensive income (loss)	(34)		—		(385)		(419)

Net Other comprehensive income (loss)	(29)		104,809		(41,878)		62,902

Balance at April 4, 2025	$	8,383	$	(8,855)	$	(64,518)	$	(64,990)

COVER PAGE - shares	3 Months Ended
COVER PAGE - shares	Apr. 03, 2026	May 01, 2026
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Apr. 03, 2026
Document Transition Report	false
Entity File Number	001-34045
Entity Registrant Name	Enovis Corp
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	54-1887631
Entity Address, Address Line One	2711 Centerville Road,
Entity Address, Address Line Two	Suite 400
Entity Address, City or Town	Wilmington,
Entity Address, State or Province	DE
Entity Address, Postal Zip Code	19808
City Area Code	(302)
Local Phone Number	252-9160
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	ENOV
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		57,562,603
Entity Central Index Key	0001420800
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2026

Financial Instruments and Fair Value Measurements - Narrative (Details) € in Millions, SFr in Millions, $ in Millions	1 Months Ended	3 Months Ended		12 Months Ended
	Jan. 31, 2025 USD ($)	Apr. 03, 2026 USD ($) contingentConsideration agreement	Apr. 04, 2025 USD ($)	Dec. 31, 2025 USD ($)	Apr. 03, 2026 EUR (€) contingentConsideration agreement	Apr. 03, 2026 CHF (SFr) contingentConsideration agreement	Apr. 04, 2025 MXN ($)	Jan. 31, 2025 CHF (SFr)
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]
Long-term debt, fair value		$ 1,300,000,000		$ 1,300,000,000
Number of contingent consideration arrangements, unlimited and based on percentage of sales in excess of benchmark \| contingentConsideration		1			1	1
Charges / (Gain)		$ 0	$ 1,787,000
Outstanding liability under agreements due within twelve months		4,247,000		6,430,000
Non-current portion of outstanding liability under agreements		31,600,000
Derivative, notional amount \| SFr								SFr 272.0
Cash received upon settlement of derivatives	$ 1,600,000
Gain recognized in other comprehensive income		5,175,000	(55,052,000)
Purchase of royalty interest		0	35,777,000	45,800,000
Royalty interest maximum gross payout		56,500,000
Currency Swap
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]
Derivative, notional amount		218,100,000				SFr 273.0
Gain recognized in other comprehensive income	$ 2,500,000	$ 6,243,000	(57,935,000)
Number of derivatives \| agreement		3			3	3
Currency Swap \| Not Designated As Hedging Instrument
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]
Mark-to-market fair value gain		$ 300,000
Cash interest benefits received		2,300,000
Currency Swap \| Net Investment Hedging
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]
Derivative, notional amount		759,900,000				SFr 951.4
Derivative, interest income		10,000,000.0	12,200,000
Forward Currency Contracts
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]
Derivative, notional amount			37,600,000				$ 763.0
Realized loss on derivative			1,100,000
Realized gain on derivative		1,000,000.0
Gain recognized in other comprehensive income		(1,068,000)	$ 2,883,000
Foreign Exchange Forward \| Not Designated As Hedging Instrument
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]
Derivative, notional amount		282,300,000			€ 130.2
Gain (loss) on derivative		7,900,000
2022 Acquisitions
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]
Contingent consideration arrangements, maximum range low		0
Contingent consideration arrangements, maximum range high		3,300,000
Fair Value, Inputs, Level 3
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]
Contingent consideration, liability		16,051,000		15,699,000
Payment for contingent consideration liability		0
Charges / (Gain)		0
Fair Value, Inputs, Level 2
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]
Deferred compensation plans asset		$ 19,800,000		$ 19,900,000

Accrued Liabilities

3 Months Ended

Apr. 03, 2026

Accrued Liabilities [Abstract]

Accrued Liabilities

Accrued liabilities in the Condensed Consolidated Balance Sheets consisted of the following:


	April 3, 2026		December 31, 2025
	(In thousands)
Accrued compensation and related benefits	$	77,090	$	105,112
Accrued taxes	60,335		27,178
Derivative liability – current portion	48,257		51,485
Accrued third-party commissions	34,691		38,174
Lease liability – current portion	25,227		24,742
Accrued rebates	21,783		31,033
Accrued professional fees	14,873		11,495
Accrued interest	9,641		4,193
Deferred and contingent consideration – current portion	6,644		8,873
Customer advances and billings in excess of costs incurred	6,082		6,495
Accrued restructuring liability	5,814		7,975
Accrued freight	5,267		4,876
Accrued royalties	4,976		4,990
Purchase of royalty interest – current portion	4,247		6,430
Warranty liability	2,633		2,621
Other	32,483		40,271
	$	360,043	$	375,943

Accrued Restructuring Liability

The Company’s restructuring programs include a series of actions to reduce the structural costs of the Company. A summary of the activity in the Company’s restructuring liability included in Accrued liabilities in the Condensed Consolidated Balance Sheets is as follows:


	Three Months Ended April 3, 2026
	Balance at Beginning of Period		Provisions		Payments		Foreign Currency Translation		Balance at End of Period
	(In thousands)
Restructuring charges:
Termination benefits(1)	$	7,975	$	1,290	$	(3,452)	$	1	$	5,814
Facility closure costs and other(2)	—		1,418		(1,418)		—		—
Total (3)	$	7,975	$	2,708	$	(4,870)	$	1	$	5,814

(1) Includes severance and other termination benefits, including outplacement services.

(3) For the three months ended April 3, 2026, $1.4 million and $1.3 million of the Company’s total provisions were related to the P&R and Recon segments, respectively.

Financial Instruments and Fair Value Measurements - Schedule of Effect of Designated Hedges Instruments on Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Jan. 31, 2025	Apr. 03, 2026	Apr. 04, 2025
Derivative [Line Items]
Gain recognized in other comprehensive income		$ 5,175	$ (55,052)
Currency Swap
Derivative [Line Items]
Gain recognized in other comprehensive income	$ 2,500	6,243	(57,935)
Forward Currency Contracts
Derivative [Line Items]
Gain recognized in other comprehensive income		$ (1,068)	$ 2,883

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Apr. 03, 2026	Apr. 04, 2025
Pay vs Performance Disclosure
Net Income (Loss)	$ (8,764)	$ (55,966)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

Equity Textual (Details)	Apr. 03, 2026 USD ($)
Equity [Abstract]
Stock repurchase program, authorized amount	$ 100,000,000

Debt - Components (Details) - USD ($) $ in Thousands	Apr. 03, 2026	Dec. 31, 2025
Debt Instrument [Line Items]
Total debt	$ 1,325,970	$ 1,296,793
Less: current portion	(35,000)	(35,000)
Long-term debt	1,290,970	1,261,793
Term loan
Debt Instrument [Line Items]
Total debt	679,130	687,697
Senior unsecured convertible notes
Debt Instrument [Line Items]
Total debt	452,685	451,938
Revolving credit facilities and other
Debt Instrument [Line Items]
Total debt	$ 194,155	$ 157,158

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 55
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482949/835-30-55-8

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(f))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69F
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482900/835-30-50-1

+ Details

- Definition

Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.

+ References + Details

Financial Instruments and Fair Value Measurements

3 Months Ended

Apr. 03, 2026

Financial Instruments and Fair Value Measurements [Abstract]

Financial Instruments and Fair Value Measurements

The Company utilizes fair value measurement guidance prescribed by accounting standards to value its financial instruments. The guidance establishes a fair value hierarchy based on the inputs used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows:

Level One: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets.

Level Two: Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

Level Three: Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

The carrying values of financial instruments, including trade receivables, other receivables and accounts payable, approximate their fair values due to their short-term maturities. The carrying value of the outstanding balances under the Enovis Credit Agreement, which bears a variable interest rate indexed to the Secured Overnight Financing Rate (SOFR), approximates fair value as it reprices when market interest rates change. Based on current interest rates for similar types of borrowings, the estimated fair value of the Company’s total debt, including the Senior unsecured convertible notes, the Term Loan, and the Revolver, was $1.3 billion and $1.3 billion as of April 3, 2026 and December 31, 2025, respectively. The estimated fair value, a Level Two valuation in the fair value hierarchy, may not represent actual values of the financial instruments that could be realized as of the balance sheet date or that will be realized in the future.

As of April 3, 2026, the Company held $16.1 million in Level Three liabilities arising from contingent consideration related to acquisitions that may settle in cash. The fair value of the contingent consideration liabilities is determined using unobservable inputs and the inputs vary based on the nature of the purchase agreements. These inputs can include the estimated amount and timing of projected cash flows, the risk-adjusted discount rate used to present value the projected cash flows, and the probability of the acquired company attaining certain targets stated within the purchase agreements. A change in these unobservable inputs to a different amount might result in a significantly higher or lower fair value measurement at the reporting date due to the nature of uncertainty inherent to the estimates.

The gross range of outcomes for contingent consideration arrangements that have a fixed limit on the maximum payout is zero to $3.3 million. There is one contingent consideration arrangement remaining that has no limit and is based on a percentage of sales in excess of benchmark through 2027.

There were no transfers in or out of Level One, Two or Three during the three months ended April 3, 2026.


	Total Contingent Consideration Rollforward
	Beginning Balance		Additions		Charges / (Gain)		Interest		Payments		Foreign Exchange		Ending Balance
	(In thousands)

Contingent Consideration - Level Three	$	15,699	$	—	$	—	$	—	$	—	$	352	$	16,051

Purchase of royalty interest liability

In the first and second quarters of 2025, the Company entered into agreements to buyout the economic interest in future royalty payments in connection with the termination of certain legacy product development agreements related to certain of the Company’s U.S. reconstructive products. The aggregate gross buyout amount under such agreements is $56.5 million, which is paid over nine years. The Company recorded charges to the Condensed Consolidated Statements of Operations of $45.8 million in the year ended December 31, 2025, representing the discounted liability upon entering the agreements. As of April 3, 2026, the outstanding liability under these agreements due within the next twelve months is $4.2 million, which is recorded in Accrued liabilities, and the non-current portion is $31.6 million, which is recorded in Other liabilities on the Condensed Consolidated Balance Sheet.

Deferred Compensation Plans

The Company maintains deferred compensation plans for the benefit of certain employees and non-executive officers. As of April 3, 2026 and December 31, 2025 the fair value of these plans were $19.8 million and $19.9 million, respectively. These plans are deemed to be Level Two within the fair value hierarchy.

Forward Currency Contracts

The Company’s objective in using forward currency contracts is to add stability to the Company’s earnings and to protect the U.S. Dollar value of forecasted transactions. To accomplish this objective, the Company had entered into forward currency contract agreements between the U.S. Dollar and the Mexican Peso as part of its risk management strategy. At December 31, 2025, the Company’s Mexican Peso forward currency contracts were fully settled and there were no notional amounts outstanding as of April 3, 2026. These forward currency contract agreements were designated and qualified as cash flow hedges.

The gain or loss on a derivative instrument designated as a cash flow hedge is recorded in Unrealized gain (loss) on hedging activities, net of tax within the Company’s unaudited Condensed Consolidated Statements of Comprehensive Income (Loss) until the underlying third-party transaction occurs. When the underlying third-party transaction occurs, the Company recognizes the gain or loss in earnings within Cost of Sales in its unaudited Condensed Consolidated Statements of Operations. The contracts are recorded at fair value and deemed to be Level Two in the fair value hierarchy.

During the three months ended April 3, 2026, the Company recognized a gain of $1.0 million in Cost of Sales on its Condensed Consolidated Statements of Operations related to its forward currency contracts designated as cash flow hedges that previously settled in the fourth quarter of 2025. At April 4, 2025, the Company’s forward currency contracts had a Mexican Peso notional amount of approximately $763.0 million and a U.S. Dollar aggregate notional amount of $37.6 million. During the three months ended April 4, 2025, the Company recognized a realized loss of $1.1 million in Cost of Sales on its Condensed Consolidated Statements of Operations related to its forward currency contracts designated as cash flow hedges.

The Company also entered into forward currency contracts on February 19, 2026 for the purpose of managing its exposure to currency exchange rate risk arising from intercompany loan balances between foreign-denominated subsidiaries. These forward currency contract agreements were designated and qualified as fair value hedges.

The gain or loss on derivative instruments designated as fair value hedges of currency exchange rate risk related to intercompany loan balances is recorded in Selling, general and administrative expense in the Condensed Consolidated Statements of Operations. This presentation is consistent with and offsets the recognition of foreign currency gains and losses resulting from the remeasurement of the hedged intercompany loan balances denominated in currencies other than their functional currencies. The contracts are recorded at fair value and deemed to be Level Two in the fair value hierarchy.

During the three months ended April 3, 2026, the Company recognized a net gain of $7.9 million on its Consolidated Statements of Operations related to the effect of exchange rate movements on its forward currency contract derivatives. At April 3, 2026, the Company had outstanding forward currency contracts with notional amounts of $130.2 million to purchase Euros and sell Swiss Francs, and $282.3 million to purchase U.S. dollars and sell Euros. These contracts mature on July 2, 2026.

Cross-currency Swap Contracts

The Company has cross-currency swap agreements to hedge its net investment in its Swiss Franc-denominated legal entity and its subsidiaries against adverse movements in exchange rates between the U.S. Dollar and the Swiss Franc. Certain of these cross-currency swap agreements are designated and qualified as net investment hedges. As of April 3, 2026, the designated cross-currency swap agreements had an aggregate Swiss Franc notional amount of approximately CHF 951.4 million and an aggregate U.S. Dollar notional amount of $759.9 million. The remaining cross-currency swap agreements were not designated as hedging instruments and had an aggregate Swiss Franc notional amount of CHF 273.0 million and an aggregate U.S. Dollar notional amount of $218.1 million as of April 3, 2026. Both the designated and undesignated cross-currency swap agreements are recorded at fair value and deemed to be Level Two in the fair value hierarchy.

Cross-currency swaps involve the receipt of functional-currency fixed-rate amounts from a counterparty in exchange for the Company making foreign-currency fixed-rate payments over the life of the agreement. For derivatives designated as net investment hedges, the change in fair value attributable to foreign currency exchange rate movements are recorded in Accumulated other comprehensive loss within the Condensed Consolidated Balance Sheet and reported as part of the foreign currency translation adjustment in the Condensed Consolidated Statements of Comprehensive Income (Loss). Amounts recorded in Accumulated other comprehensive income (loss) are reclassified out of Accumulated other comprehensive income (loss) into earnings only upon the sale or substantial liquidation of the hedged net investment.

The Company recognized interest income on its designated cross-currency swap agreements of $10.0 million and $12.2 million for the three months ended April 3, 2026 and April 4, 2025, respectively, which is included within Interest expense, net in the Condensed Consolidated Statements of Operations, consistent with the accounting for designated derivative instruments.

As of January 1, 2026, three cross-currency swap agreements previously designated as net investment hedges, with an aggregate Swiss Franc notional amount of CHF 273.0 million, were dedesignated. The dedesignation resulted from the aggregate notional amount of designated cross-currency swaps exceeding the Company’s net investment in its Swiss Franc-denominated legal entity and its subsidiaries due to the prior-year goodwill impairment charges.

For the cross-currency swap agreements that are not designated as net investment hedges, changes in fair value are recognized in non-operating Other income (expense), net in the Consolidated Statement of Operations. For the three months ended April 3, 2026, the Company recognized a mark-to-market fair value gain of $0.3 million and received $2.3 million cash interest benefit related to its undesignated cross-currency swap agreements, which are both presented within Other income (expense), net in the Consolidated Statement of Operations, consistent with the accounting for undesignated derivative instruments.

In February 2026, the Company partially reduced the excess of the cross-currency swap notional amount relative to the hedge of net investment through a legal entity restructuring. In the event the Company is unable to designate the remaining undesignated cross-currency swap agreements as net investment hedges during 2026, changes in fair value will continue to be recognized in non-operating Other income (expense), net until such time as hedge designation is achieved.

In January 2025, cross-currency swap agreements designated as net investment hedges with an aggregate Swiss Franc notional amount of CHF 272 million were de-designated and settled for a $1.6 million cash inflow reflected within investing activities in the Consolidated Statements of Cash Flows. The $2.5 million gain on settlement is reported in the Condensed Consolidated Balance Sheet as part of Accumulated other comprehensive income (loss) and in the Company’s Condensed Consolidated Statements of Comprehensive Income (Loss) as part of the foreign currency translation adjustment. The Company contemporaneously entered into new cross-currency swap agreements for the same Swiss Franc notional amount and designated them as a hedge of its net investment in its Swiss Franc-denominated subsidiaries.

The following table presents the effect of the Company’s designated hedging instruments on Accumulated other comprehensive income (loss) for the three months ended April 3, 2026 and April 4, 2025:


	Three Months Ended
	April 3, 2026		April 4, 2025
	(In thousands)
Gain (loss) on cross-currency swaps	$	6,243	$	(57,935)
Gain (loss) on forward currency contracts	(1,068)		2,883
	$	5,175	$	(55,052)

The following table presents the fair value of the Company’s derivative financial instruments as well as their classification on the Condensed Consolidated Balance Sheets as of April 3, 2026 and December 31, 2025:


(In thousands)	Location on Unaudited Consolidated Balance Sheets (1)	April 3, 2026		December 31, 2025
Derivative Assets
Designated Hedging Instruments
Forward currency contracts	Other current assets	$	7,802	$	—
Cross-currency swaps	Other current assets	22,173		34,176


		29,975		34,176
Non-Designated Hedging Instruments

Cross-currency swaps	Other current assets	$	11,112	$	—
Total Derivative Assets		$	41,087	$	34,176

Derivative Liabilities
Designated Hedging Instruments

Cross-currency swaps	Accrued liabilities	48,257		51,485

Cross-currency swaps	Other long-term liabilities	117,645		170,666
		$	165,902	$	222,151
Non-Designated Hedging Instruments

Cross-currency swaps	Other long-term liabilities	$	48,781	$	—
Total Derivative Liabilities		$	214,683	$	222,151

(1) The Company classifies derivative assets and liabilities as current when the settlement date of the contract is one year or less.

Fair Value Disclosures

Financial Instruments and Fair Value Measurements

Level One: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets.

Level Three: Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

There were no transfers in or out of Level One, Two or Three during the three months ended April 3, 2026.


	Total Contingent Consideration Rollforward
	Beginning Balance		Additions		Charges / (Gain)		Interest		Payments		Foreign Exchange		Ending Balance
	(In thousands)

Contingent Consideration - Level Three	$	15,699	$	—	$	—	$	—	$	—	$	352	$	16,051

Purchase of royalty interest liability

Deferred Compensation Plans

Forward Currency Contracts

Cross-currency Swap Contracts

The following table presents the effect of the Company’s designated hedging instruments on Accumulated other comprehensive income (loss) for the three months ended April 3, 2026 and April 4, 2025:


	Three Months Ended
	April 3, 2026		April 4, 2025
	(In thousands)
Gain (loss) on cross-currency swaps	$	6,243	$	(57,935)
Gain (loss) on forward currency contracts	(1,068)		2,883
	$	5,175	$	(55,052)


(In thousands)	Location on Unaudited Consolidated Balance Sheets (1)	April 3, 2026		December 31, 2025
Derivative Assets
Designated Hedging Instruments
Forward currency contracts	Other current assets	$	7,802	$	—
Cross-currency swaps	Other current assets	22,173		34,176


		29,975		34,176
Non-Designated Hedging Instruments

Cross-currency swaps	Other current assets	$	11,112	$	—
Total Derivative Assets		$	41,087	$	34,176

Derivative Liabilities
Designated Hedging Instruments

Cross-currency swaps	Accrued liabilities	48,257		51,485

Cross-currency swaps	Other long-term liabilities	117,645		170,666
		$	165,902	$	222,151
Non-Designated Hedging Instruments

Cross-currency swaps	Other long-term liabilities	$	48,781	$	—
Total Derivative Liabilities		$	214,683	$	222,151

(1) The Company classifies derivative assets and liabilities as current when the settlement date of the contract is one year or less.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 107
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-107

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 940
-SubTopic 820
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478119/940-820-50-1

+ Details

Debt (Tables)

3 Months Ended

Apr. 03, 2026

Debt Disclosure [Abstract]

Schedule of Debt

Long-term debt consisted of the following:


	April 3, 2026		December 31, 2025
	(In thousands)
Term loan	$	679,130	$	687,697
Senior unsecured convertible notes	452,685		451,938



Revolving credit facilities and other	194,155		157,158
Total debt	1,325,970		1,296,793
Less: current portion	(35,000)		(35,000)
Long-term debt	$	1,290,970	$	1,261,793

Acquisitions, Investments and Divestitures	3 Months Ended
Acquisitions, Investments and Divestitures	Apr. 03, 2026
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
Acquisitions, Investments and Divestitures	Acquisitions, Investments and Divestitures 2025 Acquisitions In 2025, the Company completed five business combinations and two asset acquisitions of intellectual property for total consideration of $36.9 million, including deferred and estimated contingent consideration. The business combinations include two P&R businesses and three Recon distributors, and the intellectual property asset acquisitions include one in each segment. For the transactions in P&R completed during the year ended December 31, 2025, the Company (i) paid a total of $7.8 million, net of cash received, and recorded estimated contingent consideration for future expected payments of $1.9 million for the acquisition of two businesses, and (ii) paid a total of $6.5 million in cash and recorded a $8.3 million liability for deferred payments for an asset acquisition of intellectual property. The transactions added complementary product offerings to the P&R segment. For the transactions in Recon completed during the year ended December 31, 2025, the Company (i) paid a total of $9.7 million, net of cash received, plus subsequent contingent consideration payments of approximately $1.0 million for three business combinations of distributors, and (ii) paid $1.5 million in cash for an asset acquisition of intellectual property. The transactions expanded distribution partners for the Company’s surgical implant products in Europe and added a complementary surgical product technology. The business combinations acquisitions are accounted for under the acquisition method of accounting, and accordingly, the Consolidated Financial Statements include the financial position and results of operations from the acquisition dates. The Company recorded approximately $20.7 million in definite-lived intangible assets associated with the business combinations acquisitions. The accounting for these business combinations have been finalized, and the assets and liabilities acquired are no longer subject to adjustment. The intellectual property acquisitions are accounted for as asset acquisitions. The Company also recorded an additional $16.3 million in definite-lived intangible assets associated with its asset acquisitions. 2025 Divestiture On October 7, 2025, the Company completed the divestiture of the Dr. Comfort Footcare Solutions product line of the Company’s P&R segment to Promus Equity Partners in an asset transaction that included inventory, machinery and equipment, and intangible assets for consideration of up to $60.0 million in cash, consisting of an upfront payment of $45.0 million and up to $15.0 million payable in the future upon the achievement of certain milestones (the “Dr. Comfort Divestiture”). The intangibles include all trademarks and technology of Dr. Comfort as well as U.S. customer relationships. The Dr. Comfort Divestiture does not represent a strategic shift that has a major effect on the Company’s operations and financial results and is therefore not presented as a discontinued operation. Investments As of April 3, 2026, the balance of investments held by the Company without readily determinable fair values was $22.4 million. The majority of these investments are carried at cost less impairments, if any, plus adjustments for fair value indicators from observable price changes in orderly transactions for the identical or similar investment of the same issuer. There have been no impairments or upward adjustments in the current year or since acquisition of these investments. One investment is accounted for under the equity method of accounting and is recorded at the initial investment amount, adjusted each period for the Company’s share of the income or loss.

Segment Information - Results and Reconciliation of Operating Loss to Adjusted EBITDA (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Apr. 03, 2026	Apr. 04, 2025	Dec. 31, 2025
Segment Reporting Information [Line Items]
Net sales	$ 589,151	$ 558,834
Cost of Goods and Services Sold	223,666	226,605
Research and development expense	31,533	28,528
Adjusted EBITDA (non-GAAP)	103,567	87,052
Net Loss (GAAP)	(8,450)	(55,705)
Loss from discontinued operations, net of taxes	39	125
Income tax expense (benefit)	9,045	(1,769)
Restructuring charges	2,708	3,908
MDR and other costs	1,194	3,239
Strategic transaction costs	11,032	12,054
Stock-based compensation	8,750	7,407
Depreciation and other amortization	31,449	29,624
Amortization of acquired intangibles	41,904	41,812
Purchase of royalty interest	0	35,777	$ 45,800
Interest expense, net	9,169	9,188
Other (income) expense, net	(3,273)	1,392
Adjusted EBITDA (non-GAAP) (6)	103,567	87,052
Non-recurring charges	800	2,500
Legal fees	400	700
Business exit costs	200	500
Assets	3,832,256		3,834,737
Capital expenditures	52,804	43,262
LimaCorporate S.p.A.
Segment Reporting Information [Line Items]
Strategic transaction costs	7,400	8,700
Non-Lima Acquisitions
Segment Reporting Information [Line Items]
Strategic transaction costs	3,400	2,900
Previously Reported
Segment Reporting Information [Line Items]
Adjusted EBITDA (non-GAAP)		99,200
Adjusted EBITDA (non-GAAP) (6)		99,200
Revision of Prior Period, Adjustment
Segment Reporting Information [Line Items]
Adjusted EBITDA (non-GAAP)		12,100
Adjusted EBITDA (non-GAAP) (6)		12,100
Prevention & Recovery
Segment Reporting Information [Line Items]
Net sales	272,018	272,584
Cost of Goods and Services Sold	125,757	128,764
Research and development expense	7,747	9,241
Other Cost and Expense, Operating	112,470	107,844
Operating Costs and Expenses	245,974	245,849
Depreciation	5,065	4,168
Adjusted EBITDA (non-GAAP)	31,109	30,903
Adjusted EBITDA (non-GAAP) (6)	31,109	30,903
Assets	1,450,031		1,474,243
Capital expenditures	7,201	8,793
Reconstructive
Segment Reporting Information [Line Items]
Net sales	317,133	286,250
Cost of Goods and Services Sold	97,335	97,281
Research and development expense	23,786	19,287
Other Cost and Expense, Operating	149,283	138,400
Operating Costs and Expenses	270,404	254,968
Depreciation	25,729	24,867
Adjusted EBITDA (non-GAAP)	72,458	56,149
Adjusted EBITDA (non-GAAP) (6)	72,458	56,149
Assets	2,382,225		$ 2,360,494
Capital expenditures	$ 45,603	34,469
Reconstructive \| Previously Reported
Segment Reporting Information [Line Items]
Adjusted EBITDA (non-GAAP)		68,300
Adjusted EBITDA (non-GAAP) (6)		68,300
Reconstructive \| Revision of Prior Period, Adjustment
Segment Reporting Information [Line Items]
Adjusted EBITDA (non-GAAP)		12,100
Adjusted EBITDA (non-GAAP) (6)		$ 12,100

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Apr. 03, 2026	Apr. 04, 2025
Income Statement [Abstract]
Net sales	$ 589,151	$ 558,834
Cost of sales	223,666	226,605
Gross profit	365,485	332,229
Selling, general and administrative expense	282,810	269,019
Research and development expense	31,533	28,528
Amortization of acquired intangibles	41,904	41,812
Purchase of royalty interest	0	35,777
Restructuring charges	2,708	3,862
Operating income (loss)	6,530	(46,769)
Interest expense, net	9,169	9,188
Other (income) expense , net	(3,273)	1,392
Income (loss) from continuing operations before income taxes	634	(57,349)
Income tax expense (benefit)	9,045	(1,769)
Net loss from continuing operations	(8,411)	(55,580)
Loss from discontinued operations, net of taxes	(39)	(125)
Net loss	(8,450)	(55,705)
Less: net income attributable to noncontrolling interest from continuing operations - net of taxes	314	261
Net loss attributable to Enovis Corporation	$ (8,764)	$ (55,966)
Earnings Per Share, Basic [Abstract]
Net income (loss) per share, continuing operations, basic (in usd per share)	$ (0.15)	$ (0.98)
Net income (loss) per share, continuing operations, diluted (in usd per share)	(0.15)	(0.98)
Net income (loss) per share, consolidated, basic (in usd per share)	(0.15)	(0.98)
Net income (loss) per share, consolidated, diluted (in usd per share)	$ (0.15)	$ (0.98)

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) [Parenthetical] - USD ($) $ in Thousands	3 Months Ended
	Apr. 03, 2026	Apr. 04, 2025
Statement of Comprehensive Income [Abstract]
Unrealized gain (loss) on hedging activities, tax (benefit)	$ 0	$ (13,055)
Amortization of pension net actuarial gain (loss), tax (benefit)	37	(12)
Reclassification of hedging gain (loss), (benefit) tax	$ 0	$ (118)

Income Taxes

3 Months Ended

Apr. 03, 2026

Income Tax Disclosure [Abstract]

Income Taxes


	Three Months Ended
	April 3, 2026		April 4, 2025
	(In thousands)
Loss from continuing operations before income taxes	$	634	$	(57,349)
Income tax expense (benefit)	$	9,045	$	(1,769)

The effective tax rate for the three months ended April 3, 2026 differs from the 2026 federal statutory rate of 21%, primarily due to an increase in valuation allowance on U.S. deferred tax assets, non-deductible expenses and U.S. taxation on international operations. This was partially offset by tax credits for research and development and non-U.S. income taxed at lower rates.

The effective tax rate for the three months ended April 4, 2025 differs from the 2025 U.S. federal statutory rate of 21%, primarily due to an increase in valuation allowance on interest limitation carryforwards, non-deductible expenses, and U.S. taxation on international operations. This was partially offset by tax credits for research and development and non-U.S. income taxed at lower rates.

On July 4th, 2025, the One Big Beautiful Bill Act (“OBBBA”) was enacted, introducing significant changes to U.S. tax law. The Company evaluated the potential impact of OBBBA and reflected relevant changes within the accompanying financial statements beginning in the second quarter of 2025; the most significant being an estimated increase to current year U.S. deferred tax assets for which a valuation allowance is required. The Company will continue to evaluate the changes from OBBBA, monitor developments, and assess its tax position as further guidance becomes available.

- Definition

The entire disclosure for income tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

+ Details

Revenue

3 Months Ended

Apr. 03, 2026

Revenue [Abstract]

Revenue

The Company provides orthopedic solutions, including products and services spanning the full continuum of patient care, from injury prevention to rehabilitation. While the Company’s sales are primarily derived from three sales channels including dealers and distributors, insurance, and direct to consumers and hospitals, substantially all of the Company’s revenue is recognized at a point in time. The Company disaggregates its revenue into the following geographic/product type groups within its segments:


	Three Months Ended
	April 3, 2026		April 4, 2025
	(In thousands)
Prevention & Recovery:
U.S. Bracing & Support	$	114,883	$	115,086
U.S. Other P&R	55,862		66,622
International P&R	101,273		90,876
Total Prevention & Recovery	272,018		272,584
Reconstructive:
U.S. Recon	149,208		137,877
International Recon	167,925		148,373
Total Reconstructive	317,133		286,250
Total	$	589,151	$	558,834

Given the nature of its businesses, the Company does not generally have unsatisfied performance obligations with an original contract duration of greater than one year.

The nature of the Company’s contracts gives rise to certain types of variable consideration, including rebates, implicit price concessions, and other discounts. The Company includes estimated amounts of variable consideration in the transaction price to the extent that it is probable there will not be a significant reversal of revenue.

Allowance for Credit Losses

The Company’s estimate of current expected credit losses on trade receivables considers historical credit loss information that is adjusted for current conditions and reasonable and supportable forecasts. In calculating and applying its current expected credit losses, the Company disaggregates trade receivables into business segments due to risk characteristics unique to each segment given the individual lines of business and market. The business segments are further disaggregated based on either geography or product type. The Company uses a loss rate methodology in calculating its current expected credit losses, considering historical write-offs over a defined lookback period in deriving a historical loss rate. The expected credit loss model considers current conditions and reasonable and supportable forecasts for current and projected macroeconomic factors.

A summary of the activity in the Company’s allowance for credit losses included within Trade receivables in the Condensed Consolidated Balance Sheets is as follows:


	Three Months Ended April 3, 2026
	Balance at Beginning of Period		Charged to Expense, net		Write-Offs, Deductions, and Other, net		Foreign Currency Translation		Balance at End of Period
	(In thousands)
Allowance for Credit Losses	$	25,609	$	5,149	$	(357)	$	(182)	$	30,219

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-9

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-15

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-13

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org/606/tableOfContent

+ Details

Segment Information

3 Months Ended

Apr. 03, 2026

Segment Reporting [Abstract]

Segment Information

The Company conducts its continuing operations through the Prevention & Recovery and Reconstructive operating segments, which also represent the Company’s reportable segments.

▪P&R - a leader in orthopedic solutions and recovery sciences, providing devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative disease.

•Recon - an innovation market-leader positioned in the fast-growing surgical implant business, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, and surgical productivity tools.

The Company’s management, including the chief operating decision maker, evaluates the operating results of each of its reportable segments based upon Net sales and Adjusted EBITDA. Net sales represents revenue from external customers. There are no revenues from transactions between our segments reported in our segment measures of profitability. There are certain costs incurred centrally which are allocated to the segments generally using the proportionate share of net sales. Adjusted EBITDA excludes the effect of Other (income) expense, net, non-operating (gain) loss on investments, debt extinguishment charges, interest expense, net, restructuring charges, Medical Device Regulation (MDR) and other costs, strategic transaction costs, stock-based compensation, depreciation and other amortization, acquisition-related intangible asset amortization, purchase of royalty interest, and goodwill impairment charges from the results of the Company’s operating segments.

For the three months ended April 3, 2026, we revised our definition of Adjusted EBITDA to no longer adjust for inventory step-up charges. Adjusted EBITDA in prior periods has been revised to reflect this change for consistency of presentation.

The chief operating decision maker is a group, which includes both the Company’s Chief Executive Officer and Chief Financial Officer. The chief operating decision maker uses Adjusted EBITDA because this measure assists our management in comparing operating performance over time because certain items are not normal recurring charges necessary to operate our business, and these items may obscure underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete restructuring plans and other initiatives that are fundamentally different from our ongoing productivity improvements. The chief operating decision maker utilizes Adjusted EBITDA to assess segment performance, incorporating it into the annual budgeting process and monthly comparisons of actual results to budget and updated forecasts. This analysis supports decisions regarding the allocation of capital and personnel to the segments.

The Company’s segment results were as follows:


	Three Months Ended
	April 3, 2026		April 4, 2025
	(In thousands)
Prevention & Recovery:
Net sales	$	272,018	$	272,584
Segment cost of sales	125,757		128,764
Segment research and development	7,747		9,241
Segment operating expense	112,470		107,844
Total segment expenses	245,974		245,849
Add: Depreciation	5,065		4,168
Adjusted EBITDA (non-GAAP)	$	31,109	$	30,903

Reconstructive:
Net sales	$	317,133	$	286,250
Segment cost of sales	97,335		97,281
Segment research and development	23,786		19,287
Segment operating expense	149,283		138,400
Total segment expenses	270,404		254,968
Add: Depreciation	25,729		24,867
Adjusted EBITDA (non-GAAP)(1)	$	72,458	$	56,149

Total:
Net Sales	$	589,151	$	558,834
Adjusted EBITDA (non-GAAP) (1)	$	103,567	$	87,052

(1) For the three months ended April 3, 2026, we revised our definition of Adjusted EBITDA to no longer adjust for inventory step-up charges. Adjusted EBITDA in prior periods has been revised to reflect this change for consistency of presentation. Accordingly, Adjusted EBITDA for the three months ended April 4, 2025 has been revised from $99.2 million, as presented in our Form 10-Q for the period ended April 4, 2025, to $87.1 million, reflecting the removal of a $12.1 million adjustment for inventory step-up in connection with acquired businesses. Adjusted EBITDA for our Recon segment for the three months ended April 4, 2025 has also been revised from $68.3 million, as presented in our Form 10-Q for the period ended April 4, 2025, to $56.1 million, reflecting the removal of the same $12.1 million adjustment for inventory step-up in connection with acquired businesses from the prior period.

The following is a reconciliation of Net Loss to Adjusted EBITDA:


	Three Months Ended
	April 3, 2026		April 4, 2025
	(In thousands)
Net Loss (GAAP)	$	(8,450)	$	(55,705)
Loss from discontinued operations, net of taxes	39		125
Income tax expense (benefit)	9,045		(1,769)

Restructuring charges (1)	2,708		3,908
MDR and other costs (2)	1,194		3,239
Strategic transaction costs (3)	11,032		12,054
Stock-based compensation	8,750		7,407
Depreciation and other amortization	31,449		29,624
Amortization of acquired intangibles	41,904		41,812

Purchase of royalty interest (5)	—		35,777

Interest expense, net	9,169		9,188
Other (income) expense, net (4)	(3,273)		1,392




Adjusted EBITDA (non-GAAP) (6)	$	103,567	$	87,052

(1) Restructuring charges includes immaterial expenses classified as Cost of sales on the Company’s Condensed Consolidated Statements of Operations for the three months ended April 4, 2025. There were no similar charges for the three months ended April 3, 2026.

(2) MDR and other costs includes (i) $0.8 million for the three months ended April 3, 2026 and $2.5 million for the three months ended April 4, 2025, respectively, in non-recurring costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with the medical device reporting regulations and other requirements of the new medical device regulations in the European Union for devices which were introduced to the market prior to the regulation and (ii) $0.4 million for the three months ended April 3, 2026 and $0.7 million for the three months ended April 4, 2025, respectively, of expenses to resolve certain infrequent, non-recurring regulatory or other legal matters. These costs are classified as Selling, general and administrative expense on our Condensed Consolidated Statements of Operations.

(3) Strategic transaction costs includes: (i) $7.4 million for the three months ended April 3, 2026 and $8.7 million for the three months ended April 4, 2025, respectively, related to non-recurring integration costs associated with the Lima Acquisition which includes (a) payroll and retention costs for roles eliminated in connection with the integration of our recent acquisition of Lima where a legal notice period was required prior to the employee’s separation from the Company, or integration-related daily activities not related to former roles performed by an employee during their legal notice period and prior to their separation from the Company. In each case, such costs relate solely to roles eliminated in connection with the integration of the Lima acquisition, and are non-recurring and not part of our normal business operations; (b) professional and consulting fees specifically incurred to consummate the acquisition and advise and facilitate on post-acquisition integration matters including legal entity consolidation, costs associated with rebranding and marketing acquired business under Enovis name, such as marketing materials, trade show redesign costs and product labeling; and (c) integration related costs associated with sales agent and distributor network rationalization, including contract termination and retention expenses, supply chain and portfolio integration, and quality management system consolidation, (ii) $3.4 million for the three months ended April 3, 2026 and $2.9 million for the three months ended April 4, 2025, respectively, of non-recurring (non-Lima) acquisition integration costs and other non-recurring project costs for global ERP rationalization and shared service center start-up, and (iii) $0.2 million for the three months ended April 3, 2026 and $0.5 million for the three months ended April 4, 2025, respectively, related to the Separation of our former fabrication technology business. These costs are classified as Selling, general and administrative expense on our Condensed Consolidated Statements of Operations.

(4) Includes the fair value gain adjustment for non-designated cross-currency swaps in 2026. Includes the final fair value loss adjustment for the Contingent Acquisition Shares issued in the first quarter of 2025.

(5) Purchase of royalty interest represents the one-time, up-front expense incurred by the Company to acquire the economic rights to future royalties under product development agreements in connection with the termination of such agreements as part of a strategic shift to a new product development model. The Company believes that excluding the impact of such expense enhances comparability between periods, provides investors with a clear and meaningful view of our underlying business trends and aligns with how management evaluates the ongoing business performance.

(6) For the three months ended April 3, 2026, we revised our definition of Adjusted EBITDA to no longer adjust for inventory step-up charges. Adjusted EBITDA in prior periods has been revised to reflect this change for consistency of presentation. Accordingly, Adjusted EBITDA for the three months ended April 4, 2025 has been revised from $99.2 million, as presented in our Form 10-Q for the period ended April 4, 2025, to $87.1 million, reflecting the removal of a $12.1 million adjustment for inventory step-up in connection with acquired businesses.

The Company’s total assets and capital expenditures by segment were as follows:


	April 3, 2026		December 31, 2025
	(In thousands)
Total assets(1):
Prevention & Recovery	$	1,450,031	$	1,474,243
Reconstructive	2,382,225		2,360,494
Total	$	3,832,256	$	3,834,737

(1) Includes allocation of certain centrally managed assets, including cash and cash equivalents.


	Three Months Ended
	April 3, 2026		April 4, 2025
	(In thousands)
Capital expenditures:
Prevention & Recovery	$	7,201	$	8,793
Reconstructive	45,603		34,469
Total capital expenditures	$	52,804	$	43,262

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

+ Details

Revenue - Allowance for Credit Loss Rollforward (Details) $ in Thousands	3 Months Ended
	Apr. 03, 2026 USD ($)
Financing Receivable, Allowance for Credit Loss [Roll Forward]
Balance at Beginning of Period	$ 25,609
Charged to Expense, net	5,149
Write-Offs, Deductions, and Other, net	(357)
Foreign Currency Translation	(182)
Balance at End of Period	$ 30,219

- Definition

Amount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement.

+ References + Details

Segment Information (Tables)

3 Months Ended

Apr. 03, 2026

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment

The Company’s segment results were as follows:


	Three Months Ended
	April 3, 2026		April 4, 2025
	(In thousands)
Prevention & Recovery:
Net sales	$	272,018	$	272,584
Segment cost of sales	125,757		128,764
Segment research and development	7,747		9,241
Segment operating expense	112,470		107,844
Total segment expenses	245,974		245,849
Add: Depreciation	5,065		4,168
Adjusted EBITDA (non-GAAP)	$	31,109	$	30,903

Reconstructive:
Net sales	$	317,133	$	286,250
Segment cost of sales	97,335		97,281
Segment research and development	23,786		19,287
Segment operating expense	149,283		138,400
Total segment expenses	270,404		254,968
Add: Depreciation	25,729		24,867
Adjusted EBITDA (non-GAAP)(1)	$	72,458	$	56,149

Total:
Net Sales	$	589,151	$	558,834
Adjusted EBITDA (non-GAAP) (1)	$	103,567	$	87,052

The following is a reconciliation of Net Loss to Adjusted EBITDA:


	Three Months Ended
	April 3, 2026		April 4, 2025
	(In thousands)
Net Loss (GAAP)	$	(8,450)	$	(55,705)
Loss from discontinued operations, net of taxes	39		125
Income tax expense (benefit)	9,045		(1,769)

Restructuring charges (1)	2,708		3,908
MDR and other costs (2)	1,194		3,239
Strategic transaction costs (3)	11,032		12,054
Stock-based compensation	8,750		7,407
Depreciation and other amortization	31,449		29,624
Amortization of acquired intangibles	41,904		41,812

Purchase of royalty interest (5)	—		35,777

Interest expense, net	9,169		9,188
Other (income) expense, net (4)	(3,273)		1,392




Adjusted EBITDA (non-GAAP) (6)	$	103,567	$	87,052

The Company’s total assets and capital expenditures by segment were as follows:


	April 3, 2026		December 31, 2025
	(In thousands)
Total assets(1):
Prevention & Recovery	$	1,450,031	$	1,474,243
Reconstructive	2,382,225		2,360,494
Total	$	3,832,256	$	3,834,737

(1) Includes allocation of certain centrally managed assets, including cash and cash equivalents.


	Three Months Ended
	April 3, 2026		April 4, 2025
	(In thousands)
Capital expenditures:
Prevention & Recovery	$	7,201	$	8,793
Reconstructive	45,603		34,469
Total capital expenditures	$	52,804	$	43,262

Recently Issued Accounting Pronouncements	3 Months Ended
Recently Issued Accounting Pronouncements	Apr. 03, 2026
Accounting Policies [Abstract]
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements The Company is currently reviewing updated disclosure requirements related to (“ASU”) 2024-03, Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The amendments in this ASU clarify the requirements for certain categories of expenses included in expense line items on the face of the income statement to be disclosed in a disaggregated manner in the notes to the financial statements. In addition, the update requires that the entity disclose both the total amount of selling expenses reported and how it defines selling expenses. Update No. 2024-03 is effective, as clarified by ASU No. 2025-01, for public business entities for annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. The Company is currently reviewing updated disclosure requirements related to (“ASU”) 2025-09 — Derivatives and Hedging (Topic 815): Hedge Accounting Improvements. This updates certain aspects of hedge accounting guidance to better reflect an entity’s risk management activities in its financial statements. Update No. 2025-09 is effective for all annual reporting periods beginning after December 15, 2026, and interim periods within those annual reporting periods. The Company is currently evaluating the impact of this ASU on its consolidated financial statement disclosures. Other recently issued accounting pronouncements are not expected to have a material impact on the Company's consolidated financial statements.

- Definition

The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476173/280-10-65-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-7

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483550/848-10-65-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483550/848-10-65-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483550/848-10-65-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 11.M.Q2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (i)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479654/326-10-65-4

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479654/326-10-65-4

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 926
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483194/926-20-65-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 926
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483194/926-20-65-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 926
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483194/926-20-65-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480530/250-10-S99-6

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 250
-Publisher FASB
-URI https://asc.fasb.org/250/tableOfContent

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

+ Details

CONDENSED CONSOLIDATED STATEMENT OF EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Noncontrolling Interest
Balance, beginning at Dec. 31, 2024	$ 2,564,329	$ 56	$ 2,973,121	$ (283,023)	$ (127,892)	$ 2,067
Balance, beginning (in shares) at Dec. 31, 2024		55,876,517
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(55,705)			(55,966)		261
Other comprehensive (loss) income, net of tax	63,024				62,902	122
Common stock issued for acquisition (in shares)		971,343
Common stock issued for acquisition	44,410	$ 1	44,409
Payments of tax withholding for stock-based awards	(3,447)		(3,447)
Common stock-based award activity (in shares)		270,781
Common stock-based award activity	7,607		7,607
Balance, ending at Apr. 04, 2025	2,620,218	$ 57	3,021,690	(338,989)	(64,990)	2,450
Balance, ending (in shares) at Apr. 04, 2025		57,118,641
Balance, beginning at Dec. 31, 2025	1,491,902	$ 57	3,048,414	(1,467,463)	(91,363)	2,257
Balance, beginning (in shares) at Dec. 31, 2025		57,194,781
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(8,450)			(8,764)		314
Other comprehensive (loss) income, net of tax	(12,396)				(12,396)
Payments of tax withholding for stock-based awards	(943)		(943)
Common stock-based award activity (in shares)		358,362
Common stock-based award activity	9,379	$ 1	9,378
Balance, ending at Apr. 03, 2026	$ 1,479,492	$ 58	$ 3,056,849	$ (1,476,227)	$ (103,759)	$ 2,571
Balance, ending (in shares) at Apr. 03, 2026		57,553,143

CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] - USD ($) $ in Thousands	Apr. 03, 2026	Dec. 31, 2025
Condensed Consolidated Balance Sheet (Parenthetical) [Abstract]
Trade receivables, allowance for doubtful accounts	$ 30,219	$ 25,609
Common Stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common Stock, Shares Authorized	133,333,333	133,333,333
Common Stock, Shares, Issued	57,553,143	57,194,781
Common Stock, Shares, Outstanding	57,553,143	57,194,781

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended
	Apr. 03, 2026	Apr. 04, 2025
Statement of Comprehensive Income [Abstract]
Net loss	$ (8,450)	$ (55,705)
Other comprehensive income (loss):
Foreign currency translation	(17,381)	104,928
Unrealized gain (loss) on hedging activities, net of tax expense (benefit) of $— and $(13,055)	6,243	(41,493)
Amounts reclassified from Accumulated other comprehensive income (loss):
Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, after Tax	(190)	(26)
Reclassification of hedging gain (loss), net of tax expense (benefit) of $— and $(118)	(1,068)	(385)
Other comprehensive income (loss)	(12,396)	63,024
Comprehensive income (loss)	(20,846)	7,319
Less: comprehensive income attributable to noncontrolling interest	314	383
Comprehensive Income (loss) attributable to Enovis Corporation	$ (21,160)	$ 6,936

Income Taxes (Tables)

3 Months Ended

Apr. 03, 2026

Income Tax Disclosure [Abstract]

Schedule of Components of Income Tax Expense (Benefit)


	Three Months Ended
	April 3, 2026		April 4, 2025
	(In thousands)
Loss from continuing operations before income taxes	$	634	$	(57,349)
Income tax expense (benefit)	$	9,045	$	(1,769)

Revenue (Tables)

3 Months Ended

Apr. 03, 2026

Revenue [Abstract]

Schedule of Revenue by Major Customers by Reporting Segments

The Company disaggregates its revenue into the following geographic/product type groups within its segments:


	Three Months Ended
	April 3, 2026		April 4, 2025
	(In thousands)
Prevention & Recovery:
U.S. Bracing & Support	$	114,883	$	115,086
U.S. Other P&R	55,862		66,622
International P&R	101,273		90,876
Total Prevention & Recovery	272,018		272,584
Reconstructive:
U.S. Recon	149,208		137,877
International Recon	167,925		148,373
Total Reconstructive	317,133		286,250
Total	$	589,151	$	558,834

Financing Receivable, Allowance for Credit Loss

A summary of the activity in the Company’s allowance for credit losses included within Trade receivables in the Condensed Consolidated Balance Sheets is as follows:


	Three Months Ended April 3, 2026
	Balance at Beginning of Period		Charged to Expense, net		Write-Offs, Deductions, and Other, net		Foreign Currency Translation		Balance at End of Period
	(In thousands)
Allowance for Credit Losses	$	25,609	$	5,149	$	(357)	$	(182)	$	30,219

Debt

3 Months Ended

Apr. 03, 2026

Debt Disclosure [Abstract]

Debt

Long-term debt consisted of the following:


	April 3, 2026		December 31, 2025
	(In thousands)
Term loan	$	679,130	$	687,697
Senior unsecured convertible notes	452,685		451,938



Revolving credit facilities and other	194,155		157,158
Total debt	1,325,970		1,296,793
Less: current portion	(35,000)		(35,000)
Long-term debt	$	1,290,970	$	1,261,793

Term Loan and Revolving Credit Facility

The Company’s credit agreement, which was amended December 8, 2025, consists of a $1,100 million revolving credit facility (the “Revolver”) with a December 8, 2030 maturity date and a term loan facility with an initial aggregate principal amount of $700 million (the “Term Loan”) (collectively, the “Enovis Credit Agreement”). The Revolver contains a $50 million swing line loan sub-facility. All facilities under the Enovis Credit Agreement (including the Term Loan) are guaranteed and secured by certain personal property of the Company and certain of its subsidiaries, subject to limitations and exclusions.

The Enovis Credit Agreement contains customary covenants limiting the ability of the Company and its subsidiaries to, among other things, incur debt or liens, merge or consolidate with others, dispose of assets, make investments, or pay dividends. There are also restrictions on repayments of junior financing and amendments to junior financing documents. In addition, the Enovis Credit Agreement contains financial covenants requiring the Company to maintain (i) a maximum senior secured leverage ratio of not more than 3.50:1.00 and (ii) a minimum interest coverage ratio of 3.00:1:00. The Enovis Credit Agreement contains various events of default (including failure to comply with the covenants under the Enovis Credit Agreement and related agreements), and upon an event of default the lenders may, subject to various customary cure rights, require the immediate payment of all amounts outstanding under the Enovis Credit Agreement. As of April 3, 2026, the Company was in compliance with the covenants under the Enovis Credit Agreement.

The Term Loan extended to the Company under the Enovis Credit Agreement was funded on December 8, 2025. A portion of the incremental borrowings under the Term Loan were used to repay the outstanding principal balance under the Revolver of approximately $335 million. The Term Loan requires quarterly principal repayments at 1.25% of the initial aggregate principal amount, which is $8.8 million each quarter, and matures on December 8, 2030.

As of April 3, 2026, the weighted-average interest rate of borrowings under the Enovis Credit Agreement was 5.19% excluding accretion of deferred financing fees, and there was $906 million available on the Revolver.

Convertible Notes and Capped Calls

The Company has $460 million aggregate principal senior unsecured convertible notes that were issued in October 2023 via a private placement pursuant to Rule 144A (the “2028 Notes”). The 2028 Notes have an interest rate of 3.875%, payable semiannually in arrears on April 15 and October 15 of each year, beginning April 15, 2024 and will mature on October 15, 2028 unless earlier repurchased, redeemed, or converted. The effective interest rate on the 2028 Notes is 4.6%. For the three months ended April 3, 2026, the interest expense on the 2028 Notes was $5.3 million, including $4.5 million based upon the coupon rate and $0.7 million from accretion of the discount.

Holders may convert their 2028 Notes in multiples of $1,000 principal amount prior to the close of business April 15, 2028 under the following circumstances: (i) during any calendar quarter commencing after the calendar quarter ending on December 31, 2023 (and only during such calendar quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (ii) during the five business day period after any five consecutive trading day period (the “measurement period”) in which the “trading price” per $1,000 principal amount of 2028 Notes, as determined following a request by a holder of 2028 Notes in accordance with the procedures described in the 2028 Note indenture, for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate on each such trading day; (iii) if the Company calls any or all of the 2028 Notes for redemption, at any time prior to the close of business on the second scheduled trading day immediately preceding the redemption date; or (iv) upon the occurrence of specified corporate events as described in the indenture governing the 2028 Notes.

In addition, holders may convert their 2028 Notes, in multiples of $1,000 principal amount, at their option at any time beginning on or after April 15, 2028 until the close of business on the second scheduled trading day immediately preceding the maturity date, regardless of the foregoing circumstances. The conversion rate is 17.1474 shares of common stock per $1,000 principal amount of 2028 Notes (equivalent to an initial conversion price of approximately $58.32 per share of common stock), subject to adjustment upon the occurrence of certain specified events as set forth in the indenture governing the 2028 Notes. Upon conversion, the Company will pay cash up to the aggregate principal amount of the 2028 Notes to be converted and pay or deliver, as the case may be, cash, shares of common stock or a combination of cash and shares of common stock, at its election, in respect of the remainder. There have been no redemptions or conversions of the 2028 Notes.

The Company also entered into privately negotiated capped call transactions in October 2023 with certain of the initial purchasers of the 2028 Notes. The capped call transactions are intended generally to mitigate potential dilution to the Company’s common stock upon conversion of any Notes and/or offset any cash payments the Company is required to make in excess of the principal amount of converted notes, as the case may be, with such reduction and/or offset subject to a cap. If, however, the market price per share of common stock exceeds $89.72, the initial cap price of the capped call transactions, there would be a dilutive effect and/or no offset of any cash payments, in each case, attributable to the amount by which the market price of the common stock exceeds the cap price.

Other Indebtedness

In addition to the debt agreements discussed above, the Company is party to overdraft facilities with a borrowing capacity of $30.0 million. Total letters of credit and surety bonds of $49.6 million were outstanding as of April 3, 2026.

Deferred Financing Fees

As of April 3, 2026, the Company has $5.3 million in deferred financing fees included in Other assets related to the Revolver and $10.7 million of original issue discount fees and other issuance costs included as a reduction of Long-term debt related to the Term Loan and the 2028 Notes.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/470/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

+ Details

Net Income (Loss) Per Share from Continuing Operations (Tables)

3 Months Ended

Apr. 03, 2026

Earnings Per Share [Abstract]

Schedule of Loss Per Share from Continuing Operations

Net income (loss) per share from continuing operations was computed using the treasury stock method as follows:


	Three Months Ended
	April 3, 2026		April 4, 2025
	(In thousands, except share and per share data)
Computation of Net income (loss) per share from continuing operations - basic:
Net income (loss) from continuing operations attributable to Enovis Corporation(1)	$	(8,725)	$	(55,841)
Weighted-average shares of Common stock outstanding – basic	57,313,036		56,791,836
Net income (loss) per share from continuing operations – basic	$	(0.15)	$	(0.98)

Computation of Net income (loss) per share from continuing operations - diluted:
Net income (loss) from continuing operations attributable to Enovis Corporation(1)	$	(8,725)	$	(55,841)
Weighted-average shares of Common stock outstanding – basic	57,313,036		56,791,836
Net effect of potentially dilutive securities - stock options and restricted stock units	—		—
Weighted-average shares of Common stock outstanding – diluted	57,313,036		56,791,836
Net income (loss) per share from continuing operations – diluted	$	(0.15)	$	(0.98)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

Three Months Ended

April 3, 2026

April 4, 2025

Anti-dilutive shares

2,301,362

1,867,454

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Apr. 03, 2026	Dec. 31, 2025
ASSETS
Cash and cash equivalents	$ 33,129	$ 36,389
Trade receivable, less allowance for credit losses	444,206	442,786
Inventories, net	602,543	584,379
Prepaid expenses	49,517	42,283
Other current assets	110,286	101,222
Total current assets	1,239,681	1,207,059
Property, plant and equipment, net	519,721	507,063
Goodwill	711,903	718,299
Intangible assets, net	1,192,487	1,236,713
Lease asset - right of use	74,500	72,256
Other assets	93,964	93,347
Total assets	3,832,256	3,834,737
LIABILITIES AND EQUITY
Current portion of long-term debt	35,000	35,000
Accounts payable	213,622	187,531
Accrued liabilities	360,043	375,943
Total current liabilities	608,665	598,474
Long-term debt, less current portion	1,290,970	1,261,793
Non-current lease liability	59,324	58,000
Other liabilities	393,805	424,568
Total liabilities	2,352,764	2,342,835
Equity:
Common stock, $0.001 par value; 133,333,333 shares authorized; 57,553,143 and 57,194,781 shares issued and outstanding as of April 3, 2026 and December 31, 2025, respectively	58	57
Additional paid-in capital	3,056,849	3,048,414
Accumulated deficit	(1,476,227)	(1,467,463)
Accumulated other comprehensive loss	(103,759)	(91,363)
Total Enovis Corporation equity	1,476,921	1,489,645
Noncontrolling interest	2,571	2,257
Total equity	1,479,492	1,491,902
Total liabilities and equity	$ 3,832,256	$ 3,834,737

Financial Instruments and Fair Value Measurements (Tables)

3 Months Ended

Apr. 03, 2026

Financial Instruments and Fair Value Measurements [Abstract]

Schedule of Business Acquisitions by Acquisition, Contingent Consideration


	Total Contingent Consideration Rollforward
	Beginning Balance		Additions		Charges / (Gain)		Interest		Payments		Foreign Exchange		Ending Balance
	(In thousands)

Contingent Consideration - Level Three	$	15,699	$	—	$	—	$	—	$	—	$	352	$	16,051

Schedule of Effect of Designated Hedges Instruments on Accumulated Other Comprehensive Income (Loss)

The following table presents the effect of the Company’s designated hedging instruments on Accumulated other comprehensive income (loss) for the three months ended April 3, 2026 and April 4, 2025:


	Three Months Ended
	April 3, 2026		April 4, 2025
	(In thousands)
Gain (loss) on cross-currency swaps	$	6,243	$	(57,935)
Gain (loss) on forward currency contracts	(1,068)		2,883
	$	5,175	$	(55,052)

Schedule of Derivative Instruments in Statement of Financial Position, Fair Value


(In thousands)	Location on Unaudited Consolidated Balance Sheets (1)	April 3, 2026		December 31, 2025
Derivative Assets
Designated Hedging Instruments
Forward currency contracts	Other current assets	$	7,802	$	—
Cross-currency swaps	Other current assets	22,173		34,176


		29,975		34,176
Non-Designated Hedging Instruments

Cross-currency swaps	Other current assets	$	11,112	$	—
Total Derivative Assets		$	41,087	$	34,176

Derivative Liabilities
Designated Hedging Instruments

Cross-currency swaps	Accrued liabilities	48,257		51,485

Cross-currency swaps	Other long-term liabilities	117,645		170,666
		$	165,902	$	222,151
Non-Designated Hedging Instruments

Cross-currency swaps	Other long-term liabilities	$	48,781	$	—
Total Derivative Liabilities		$	214,683	$	222,151

(1) The Company classifies derivative assets and liabilities as current when the settlement date of the contract is one year or less.

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Apr. 03, 2026
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies The Company is involved in various pending legal, regulatory, and other proceedings arising out of the ordinary course of the Company’s business. None of these proceedings are expected to have a material adverse effect on the financial condition, results of operations or cash flow of the Company. With respect to these proceedings, management of the Company believes that either it will prevail, has adequate insurance coverage or has established appropriate accruals to cover potential liabilities. Legal costs related to proceedings or claims are recorded as incurred. Other costs that management estimates may be paid related to the claims are accrued when the liability is considered probable and the amount can be reasonably estimated. There can be no assurance, however, as to the ultimate outcome of any of these matters, and if all or substantially all of these proceedings were to be determined adverse to the Company, there could be a material adverse effect on the financial condition, results of operations or cash flow of the Company. For further description of the Company’s litigation and contingencies, reference is made to Note 18, “Commitments and Contingencies” in the Notes to Consolidated Financial Statements in the Company’s 2025 Form 10-K.